Next Science Limited (NXS.AX)
AUD 0.12
(0.0%)
AUD 0.12
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 687.16 Thousand USD | -28.57% |
| 2022 | 962.06 Thousand USD | 776.18% |
| 2021 | 109.8 Thousand AUD | -5.25% |
| 2020 | 115.88 Thousand AUD | -59.48% |
| 2019 | 286.01 Thousand AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2023 Q2 | 7.25 Million USD | 653.99% |
| 2023 FY | 687.16 Thousand USD | -28.57% |
| 2023 Q4 | 687.16 Thousand USD | -90.53% |
| 2022 Q2 | 1.09 Million USD | 897.39% |
| 2022 FY | 962.06 Thousand USD | 776.18% |
| 2022 Q4 | 962.06 Thousand USD | -12.15% |
| 2021 Q2 | 169.89 Thousand USD | 12.91% |
| 2021 FY | 109.8 Thousand AUD | -5.25% |
| 2021 Q4 | 109.8 Thousand AUD | -35.37% |
| 2020 Q2 | 198.51 Thousand USD | -30.59% |
| 2020 FY | 115.88 Thousand AUD | -59.48% |
| 2020 Q4 | 150.46 Thousand AUD | -24.2% |
| 2019 FY | 286.01 Thousand AUD | 0.0% |
| 2019 Q4 | 286.01 Thousand AUD | -25.99% |
| 2019 Q2 | 386.42 Thousand USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Althea Group Holdings Limited | - AUD | -Infinity% |
| Cann Group Limited | 421 Thousand AUD | -63.222% |
| ECS Botanics Holdings Ltd | - AUD | -Infinity% |
| Ecofibre Limited | 9.5 Million AUD | 92.767% |
| Elixinol Wellness Limited | 178 Thousand AUD | -286.047% |
| Hygrovest Limited | - AUD | -Infinity% |
| IDT Australia Limited | - AUD | -Infinity% |
| Invion Limited | - AUD | -Infinity% |
| Little Green Pharma Ltd | 5.31 Million AUD | 87.063% |
| Live Verdure Ltd | - AUD | -Infinity% |
| Medical Developments International Limited | 1.91 Million AUD | 64.117% |
| Vitura Health Limited | 4.11 Million AUD | 83.317% |
| Vita Life Sciences Limited | 176 Thousand AUD | -290.434% |